MedTrace Logo

Clinical Study of Vitamin B5 in Adjuvant Treatment of IBD

NCT05701501 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2023-06-15

No results posted yet for this study

Summary

Patients with IBD are randomized to oral administration of vitamin B5 and placebo based on the standard treatment, exploring whether Vitamin B5 can increase the clinical remission rate of IBD patients and improve the treatment effect.

Conditions

  • Inflammatory Bowel Diseases

Interventions

DRUG

Vitamin B5 Tablets

The experimental group was given Vitamin tablets (5mg/tablet) based on the standard IBD treatment.

DRUG

placebo

The control group was given placebo tablets of the same type based on the standard IBD treatment.

Sponsors & Collaborators

  • The University of Science and Technology of China

    collaborator OTHER

  • Changhai Hospital

    lead OTHER

Principal Investigators

  • Zhaoshen Li, MD · Changhai Hospital

  • Shu Zhu, PhD · The University of Science and Technology of China

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-01
Primary Completion
2024-02-01
Completion
2024-02-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05701501 on ClinicalTrials.gov